<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787163</url>
  </required_header>
  <id_info>
    <org_study_id>Amnioinfusion-001</org_study_id>
    <nct_id>NCT00787163</nct_id>
  </id_info>
  <brief_title>Amnioinfusion Initiative</brief_title>
  <official_title>Open Randomized Trial Comparing Perinatal Outcome Following Expectant Management Versus Amnioinfusion in PPROM &lt;25 Wks With Persistent Oligohydramnios</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Università degli Studi di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare perinatal survival in patients presenting with early&#xD;
      spontaneous PPROM and persistent oligohydramnios, managed either conservatively or with&#xD;
      serial amnioinfusions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early spontaneous Preterm Premature Rupture of Membranes (PPROM) is associated with high&#xD;
      perinatal mortality. Due to pulmonary hypoplasia and preterm delivery, mortality exceeds 60%&#xD;
      when PPROM occurs prior to 24 weeks. When oligohydramnios persists, it may raise to 90%.&#xD;
      Morbidity in survivors is also significant. In uncontrolled series, serial amnioinfusions,&#xD;
      which have acceptable invasiveness and are of limited complexity, mortality was reduced to&#xD;
      60%.&#xD;
&#xD;
      We propose an open, multicenter randomized trial comparing perinatal survival in patients&#xD;
      presenting with early spontaneous PPROM and persistent oligohydramnios, managed either&#xD;
      conservatively or with serial amnioinfusions. Inclusion criteria: Single pregnancy, early&#xD;
      spontaneous PPROM &lt; 24.3 weeks, oligohydramnios (deepest vertical pocket &lt; 2 cm) for at least&#xD;
      4 days and no longer than 15 days at enrolment. The study is open and will be run through a&#xD;
      dedicated password protected web site, and with a minimal number of outcome measures. Primary&#xD;
      outcome: Survival till discharge from the NICU. Secondary outcomes: Latency time from PPROM&#xD;
      to delivery, gestational age at birth, indication for delivery, number of days of ventilatory&#xD;
      support, serious neurologic morbidity, neonatal sepsis prevalence, need for oxygen at 36&#xD;
      weeks post-conception.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival of neonates/infants at discharge after serial amnioinfusions compared to survival after expectant management</measure>
    <time_frame>discharge of every neonate from NICU</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age of delivery (main secondary outcome)</measure>
    <time_frame>time of delivery for every case</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Oligohydramnios</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amnioinfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>expectant management</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>amnioinfusion</intervention_name>
    <description>serial amnioinfusions aimed at restoring amniotic fluid volume</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients above 18 years, who are able to consent, with&#xD;
&#xD;
          2. Singleton pregnancy&#xD;
&#xD;
          3. with a normal structural examination as much as possible;&#xD;
&#xD;
          4. At least 2 US examination after pPROM for gestational age confirmation and diagnosis&#xD;
             of persistent oligohydramnios&#xD;
&#xD;
          5. Follow up ultrasound examinations weekly in the treatment group&#xD;
&#xD;
          6. Acceptance of randomisation and to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Maternal contra-indications to intervention or prolongation of pregnancy, including&#xD;
             severe medical conditions in pregnancy that make fetal intervention riskful;&#xD;
&#xD;
          2. Preterm labour defined as contractions &gt;6/hour associated with cervical changes,&#xD;
             cervix shortened (&lt;15 mm at randomization),&#xD;
&#xD;
          3. Cervical cerclage in place&#xD;
&#xD;
          4. Chorioamnionitis, defined as 2 or more of the following: maternal temperature&gt;38&#xD;
             degrees, foul-smelling vaginal discharge, uterine tenderness, fetal tachycardia&gt;170&#xD;
             bpm, white blood cell count &gt;18,000&#xD;
&#xD;
          5. Fetal structural anomaly detected at prenatal ultrasonography, or fetal chromosomal&#xD;
             abnormalities involving autosomes&#xD;
&#xD;
          6. Previous invasive procedure in this index pregnancy&#xD;
&#xD;
          7. Fetal condition mandating immediate delivery&#xD;
&#xD;
          8. Severe bleeding&#xD;
&#xD;
          9. Maternal HIV and HCV infection&#xD;
&#xD;
         10. Multiple gestation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Locatelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milano Bicocca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrizia Vergani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Milano Bicocca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Locatelli, MD</last_name>
    <phone>+39 039 233 4720</phone>
    <email>anna.locatelli@unimib.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Milano Bicocca, Ospedale san Gerardo Monza</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Locatelli, MD</last_name>
      <phone>+390392334720</phone>
      <email>anna.locatelli@unimib.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <last_update_submitted>January 21, 2009</last_update_submitted>
  <last_update_submitted_qc>January 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Anna Locatelli</name_title>
    <organization>University of Milano Bicocca</organization>
  </responsible_party>
  <keyword>pPROM</keyword>
  <keyword>oligohydramnios</keyword>
  <keyword>amnioinfusion</keyword>
  <keyword>prematurity</keyword>
  <keyword>Early premature rupture of membranes in pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligohydramnios</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

